Compare Abeona Therapeutics Inc (ABEO) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Flux Power Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Flux Power Holdings Inc trades at $0.73 (market cap $16.02M). The key difference: Abeona Therapeutics Inc is far larger — about 23.3× Flux Power Holdings Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FLUX | |
|---|---|---|
Market Cap | $373.32M | $16.02M |
Sector | Health | Utilities |
52-Week High | $7.23 | $6.66 |
52-Week Low | $4.17 | $0.75 |
Enterprise Value | $228.22M | $22.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FLUX trades at $0.8199, down 8.75% over 24 hours. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $6.67 million in 2025 with a negative net margin of 12.48%, while revenue declined to $51 million in 2026. Recent developments include the launch of SkyEMS 3.0 AI software and new executive appointments aimed at growth.
Outlook remains speculative with unanimous analyst buy ratings contrasting weak profitability. Key opportunities lie in software innovation and market expansion, but risks include persistent losses, revenue volatility, and intense clean energy competition. The stock's appeal hinges on execution turning losses to profits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
